FISIOLOGÍA Y FARMACOLOGÍA
Departamento
Dana–Farber Cancer Institute
Boston, Estados UnidosPublicaciones en colaboración con investigadores/as de Dana–Farber Cancer Institute (3)
2021
-
Biological significance of monoallelic and biallelic BIRC3 loss in del(11q) chronic lymphocytic leukemia progression
Blood Cancer Journal, Vol. 11, Núm. 7
2020
-
CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition
Leukemia, Vol. 34, Núm. 6, pp. 1599-1612
2007
-
Normal cellular senescence and cancer susceptibility in mice genetically deficient in Ras-induced senescence-1 (Ris1)
Oncogene, Vol. 26, Núm. 12, pp. 1673-1680